Non-Consolidated Financial Results (Japanese GAAP)
for the Six Months Ended June 30, 2025

August 12, 2025

Company Name: Chiome Bioscience Inc. Tokyo Stock Exchange
Stock Code: 4583 URL https://www.chiome.co.jp/?id=en
Representative: Masamichi Koike, President & CEO
Inquiries: Arihiko Bijohira, Executive Director & CFO TEL: +81-3-6383-3561
Scheduled filing date of semi-annual securities report: August 12, 2025
Scheduled dividend payment commencement date: —
Supplementary materials prepared for the quarterly financial results: Yes
Holding of the quarterly financial results explanatory meeting: Yes (For institutional investors and securities analysts)

(Amounts of less than one million yen are rounded down)

1. Financial Results for the Six Months Ended June 30, 2025 (January 1, 2025 to June 30, 2025)

(1) Operating Results (Cumulative)

(% figures are the increase / (decrease) compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net Income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended Jun. 30, 2025	251	(4.5)	(536)	—	(539)	—	(540)	—
Six months ended Jun. 30, 2024	263	(26.5)	(581)	—	(563)	—	(563)	—

	Net Income per Share	Diluted Net Income per Share
	Yen	Yen
Six months ended Jun. 30, 2025	(7.97)	—
Six months ended Jun. 30, 2024	(10.21)	—

Notes: Despite the existence of shares with a dilutive effect, "Diluted Net Income per Share" is not stated because Chiome incurred a loss for each respective period.

(2) Financial Position

	Total Assets	Net Assets	Equity Ratio
	Million yen	Million yen	%
As of Jun. 30, 2025	1,962	1,519	76.9
As of Dec. 31, 2024	2,468	1,920	77.4

(Reference) Equity As of Jun. 30, 2025: 1,510 million yen As of Dec. 31, 2024: 1,910 million yen

2. Dividends

	Annual Dividends				
	1Q-End	2Q-End	3Q-End	FY-End	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal Year Ending Dec. 31, 2024	—	0.00	—	0.00	0.00
Fiscal Year Ending Dec. 31, 2025	—	0.00			
Fiscal Year Ending Dec. 31, 2025 (Forecast)			—	0.00	0.00

Note: Revision to the most recently announced dividend forecast: No

3. Forecasts of Financial Results for the Fiscal Year Ending December 31, 2025 (January 1, 2025 to December 31, 2025)

As it is difficult to provide reasonable estimates for Drug Discovery and Development Business at present, Chiome discloses only business forecasts for Drug Discovery Support Business; net sales ¥500 million. There is no revision to the most recently announced forecasts of financial results.

[Notes]

(1) Application of Special Accounting Practices in the Preparation of Quarterly Financial Statements: No

(2) Changes in Accounting Policies, Changes in Accounting Estimates, and Retrospective Restatements
- 1) Changes in accounting policies in line with revisions to accounting and other standards: No
- 2) Changes in accounting policies other than 1) above: No
- 3) Changes in accounting estimates: No
- 4) Retrospective restatements: No

(3) Number of Shares Issued (Common Stock)

1) Number of shares issued as of the end of the period (including treasury stock)	As of Jun. 30, 2025	68,053,800 shares	As of Dec. 31, 2024	66,969,000 shares
2) Number of treasury stock as of the end of the period	As of Jun. 30, 2025	12,149 shares	As of Dec. 31, 2024	12,149 shares
3) Average number of shares for the period (cumulative total for the period)	Six months ended Jun. 30, 2025	67,754,994 shares	Six months ended Jun. 30, 2024	55,249,986 shares

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or audit firms: No

* Explanation Concerning the Proper Use of Financial Results Forecasts and Other Relevant Specific Items

1. Forward-looking statements including forecasts of financial results contained in this report are based on management's assumptions and beliefs that are determined to be reasonable in light of currently available information. Chiome cautions readers that due to a variety of factors actual results may differ materially from forecasts. For the assumptions that underpin financial results forecasts as well as other related items, please refer to the "1. Qualitative Information Regarding Interim Financial Results (3) Explanation of Forward-Looking Statements including Financial Forecasts" on page 5 of this report.
2. Chiome plans to hold a financial results explanatory meeting for institutional investors and securities analysts on August 26, 2025. Supplementary materials will be available on the Chiome's website after the meeting.

Contents

1. Qualitative Information Regarding Interim Financial Results

(1) Overview of Operating Results in the Interim Period under Review

Our company operates a drug discovery business, mainly developing antibody drugs for areas with high unmet needs, utilizing our antibody generation technology and drug discovery know-how, and operates a drug discovery support business that offers services such as antibody generation and protein expression/purification to pharmaceutical companies and academia.

An overview of the Company's business activities during the current interim accounting period is as follows.

In the drug discovery business, Phase I clinical studies are underway for CBA-1535 and CBA-1205; both are in-house developed therapeutic antibodies for cancer. In CBA-1205, patient enrollment for the patients with hepatocellular carcinoma and melanoma is in progress. In addition, we are considering adding a part for pediatric cancer, which has high unmet needs, within this year. In CBA-1535, a multi-specific antibody for cancer treatment, we continue the dose escalation to assess the safety in patients with solid tumors. For other drug discovery pipeline products, introductions and discussions are underway with companies that are potential candidates for out-licensing.

In the drug discovery support business, while focusing on maintaining strong relationships with existing major clients, we continue to promote activities to stabilize its revenue base by acquiring new clients in the interim period.

During the interim period, we launched a new IDD business (a platform-based initiative for antibody drug discovery and development) and are currently in discussions with potential partner companies to establish its operational framework. We are advancing efforts to develop new biosimilar medical products as part of our initiatives in the IDD business based on the business alliance agreement concluded with Kidswell Bio Corporation (Kidswell) in June last year. In May 2025, our company, Alfresa Holdings and Kidswell applied for the public offering related to the Ministry of Health, Labour and Welfare (MHLW)'s Subsidy Program, and our joint application was selected. We are making steady progress in our activities towards new biosimilar medical product development together with a 4th company, Mycenax Biotech Inc., a Taiwan-based contract development and manufacturing organization.

We have also entered into a business alliance agreement with SRD Corporation Ltd. in March, 2025 as a part of IDD business initiatives aimed at applying our expertise to drug discovery and development, and the fostering of drug discovery ventures. In this business, we provide consulting services for antibody drug discovery seeds at drug discovery venture companies to generate revenue.

The Company's performance for the interim period is as follows: net sales of ¥251,796 thousand (a decrease of ¥11,932 thousand year-on-year), R&D expenses amounted to ¥395,868 thousand (a decrease of ¥50,949 thousand year-on-year), operating loss of ¥536,822 thousand (operating loss of ¥581,136 thousand in the same period of the previous year), ordinary loss of ¥539,020 thousand (ordinary loss of ¥563,345 thousand in the same period of the previous year), net loss of ¥540,290 thousand (net loss of ¥563,958 thousand in the same period of the previous year). For R&D expenses, the recorded amount of clinical development-related costs mainly decreased compared to the same period of the previous year. As a result, operating loss, ordinary loss, and net loss for the period all showed reduced deficits year-on-year.

An overview of the Company's business activities during the interim period is as follows.

1) Drug Discovery Business

- Drug Discovery Pipeline (out-licensed products)

PFKR is a therapeutic antibody candidate for autoimmune disease in CNS area targeting CX3CR1, a type of G protein-coupled receptor (GPCR). Our company and the National Center of Neurology and Psychiatry are progressing with a joint research program. We entered into an exclusive license agreement with Asahi Kasei Pharma in November 2024 and the company is preparing to start preclinical studies.

- Drug Discovery Pipeline (In-house programs, out-licensing candidates)

For CBA-1205, we are conducting the second part of the Phase I clinical study in Japan to evaluate safety and efficacy in patients with hepatocellular carcinoma and melanoma. Furthermore, joint research with a research institute in Europe suggested the potential efficacy of anti-DLK-1 antibodies against pediatric solid tumors, and the antibody has shown high safety from adult patients dosing results which makes administration to children possible. Therefore, we were working on adding a cohort for pediatric cancer patients within this year. We will advance clinical development to obtain data aimed at maximizing product value and out-licensing potential, by evaluating safety and tolerability in pediatric patients, in addition to patients with melanoma and hepatocellular carcinoma. Notably, a melanoma patient enrolled in the first part has been dosed with CBA-1205 for more than 48 months and has maintained a stable disease (SD) assessment with tumor shrinkage.

A Phase I clinical study of CBA-1535 in patients with solid tumors is also underway in Japan. In the first part, we evaluate the safety and tolerability of CBA-1535 as a single agent, and in the second part, in combination with a checkpoint inhibitor. Currently, the first part is in progress, and so far, no adverse events raising development concerns have been observed. The change in blood biomarkers has started to show which indicates T-cell activation, the mechanism of action of the study drug. Regarding the starting date of the second part, we will begin after confirming the efficacy signals of the single agent in the first part of the study. We will continue to advance clinical studies while keeping future out-licensing opportunities in mind using the clinical data of the first part.

PTRY is a Tribody® antibody and is expected to add immune checkpoint inhibitory function on the T-cell engager function of CBA-1535. Its initial evaluations using animal models have shown strong anti-tumor effects. For the development of this product, we have decided to prioritize out-licensing to other pharmaceutical companies who can enter commercialization and clinical development rather than carrying out early clinical development by ourselves. This is because we can expect licensing out in pre-clinical stages, depending on the development status of CBA-1535.

For PCDC, we are conducting out-licensing activities for PCDC, a humanized anti-CDCP1 antibody, with a focus on antibody drug conjugate (ADC) applications. Amid growing global interest in ADCs, we are promoting out-licensing activities with pharmaceutical companies that own ADC technologies.

PXLR is a humanized antibody targeting CXCL1 for cancer therapy. CXCL1 is highly expressed in cancers such as gastric and pancreatic cancers. It is a new candidate for out-licensing, and a joint research program with Osaka Metropolitan University is in progress.

- IDD Business

Our company has been promoting the creation of drug seeds and making them into intellectual property to expand our pipeline and explore out-licensing opportunities. In addition, we are currently focusing on collaboration with

pharmaceutical companies using our technology and know-how related to antibody drug discovery to enhance profitability through IDD business.

As a result of the above, results for the interim period in the drug discovery business are as follows: R&D expenses amounted to ¥395,868 thousand due to the progress of clinical development (a decrease of ¥50,949 thousand year-on-year), and segment loss of ¥395,868 thousand (segment loss of the same period last year was ¥446,817 thousand).

2) Drug Discovery Support Business

The drug discovery support business contributes to the company's stable earnings. We provide research support by undertaking antibody production using our antibody technology ADLib® system, and we are also developing research support services for biopharmaceuticals, mainly for major domestic pharmaceutical companies such as Ono Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd. Our technical service capabilities are highly recognized by our client companies. During the interim period, we continued to acquire new clients including Nitto Boseki Co., Ltd. to promote the activities to stabilize its revenue base.

The results for the interim period in the drug discovery support business are as follows: net sales of ¥251,796 thousand (a decrease of ¥11,932 thousand year-on-year), segment profit of ¥138,866 thousand (an increase of ¥4,107 thousand year-on-year), and segment profit margin of 55.2% (target 50%).

(2) Overview of Finance Position in the Interim Period under Review

(i) Assets, Liabilities and Net Assets

(Assets)

Total assets at the end of the interim period amounted to ¥1,962,725 thousand, a decrease of ¥506,131 thousand from the end of the previous fiscal year, mainly due to the decrease in cash on hand and in banks.

(Liabilities)

Total liabilities at the end of the interim period amounted to ¥443,394 thousand, a decrease of ¥105,158 thousand from the end of the previous fiscal year. This is mainly due to a decrease of accounts payable, other.

(Net assets)

Total net assets at the end of the interim period amounted to ¥1,519,330 thousand, a decrease of ¥400,973 thousand. This was mainly due to a decrease in retained earnings resulting from the recording of an interim net loss.

(ii) Cash Flows

The balance of cash and cash equivalents (hereinafter "funds") at the end of the interim period was ¥1,474,952 thousand, a decrease of ¥588,328 thousand from the end of the previous fiscal year. The status of each cash flow and its main factors are as follows.

(Cash flows from operating activities)

Funds used in operating activities amounted to ¥673,006 thousand during the interim period. The main reason for this was recording of an interim loss before tax.

(Cash flows from investing activities)

There were no changes in cash flows from investing activities during the interim period.

(Cash flows from financing activities)

Funds acquired in operating activities during the interim period amounted to ¥84,678 thousand. This was mainly due to the proceeds from the issue of shares as a result of the exercise of subscription rights.

(3) Explanation of Forward-Looking Statements including Financial Forecasts

There are no changes to the financial results forecasts for the fiscal year ending December 31, 2025, announced on February 13, 2025.

The impact of the U.S. reciprocal tariff measures on our business operations is currently expected to be minimal.

2. Interim Financial Statements

(1) Interim Balance Sheets

Thousand yen

	As of Dec. 31, 2024	As of Jun 30, 2025
Assets		
Current assets		
Cash on hand and in banks	2,063,280	1,474,952
Accounts receivable	51,063	39,373
Inventories	46,171	46,666
Advance payment-trade	101,992	104,242
Consumption taxes receivable	24,425	16,090
Other current assets	50,738	149,161
Total current assets	2,337,672	1,830,487
Non-current assets		
Property and equipment		
Machinery	230,491	222,675
Accumulated depreciation	(230,491)	(222,675)
Machinery, net	0	0
Tools and equipment	82,364	82,364
Accumulated depreciation	(82,364)	(82,364)
Tools and equipment, net	0	0
Total property and equipment	0	0
Investments and other assets		
Long-term prepaid expenses	18,375	19,429
Lease deposits and others	112,809	112,808
Others	0	0
Total investments and other assets	131,184	132,237
Total non-current assets	131,185	132,238
Total assets	2,468,857	1,962,725

Thousand yen

	As of Dec. 31, 2024	As of Jun. 30, 2025
Liabilities		
Current liabilities		
Accounts payable, trade	27,196	36,828
Short-term borrowings	281,500	260,500
Accounts payable, other	138,103	62,871
Accrued expenses	29,557	11,432
Income taxes payable	2,531	10,327
Deposits received	14,543	6,096
Total Current liabilities	493,432	388,057
Non-current liabilities		
Asset retirement obligations	55,120	55,336
Total non-current liabilities	55,120	55,336
Total liabilities	548,553	443,394
Net assets		
Shareholders' equity		
Capital stock	995,525	1,065,558
Capital reserve	1,935,799	2,005,832
Retained earnings	(1,020,776)	(1,561,066)
Treasury stock	(292)	(292)
Total shareholders' equity	1,910,255	1,510,032
Share acquisition rights	10,048	9,298
Total net assets	1,920,303	1,519,330
Total liabilities and net assets	2,468,857	1,962,725

(2) Interim Statement of Income

Thousand yen

	Six Months Ended Jun. 30, 2024 (Jan. 1, 2024 to Jun. 30, 2024)	Six Months Ended Jun. 30, 2025 (Jan. 1, 2025 to Jun. 30, 2025)
Net sales	263,728	251,796
Cost of sales	128,970	112,930
Gross profit	134,758	138,866
Selling, general and administrative expenses		
Research and development expenses	446,817	395,868
Other, net	269,077	279,819
Total selling, general and administrative expenses	715,894	675,688
Operating loss	(581,136)	△536,822
Non-operating income		
Interest income	20	910
Foreign exchange gains	519	220
Subsidy income	19,738	―
Other, net	798	132
Total non-operating income	21,077	1,263
Non-operating expenses		
Interest expenses	1,282	1,940
Share issuance cost	2,004	1,521
Other, net	0	―
Total non-operating expenses	3,286	3,462
Ordinary loss	(563,345)	(539,020)
Extraordinary income		
Gain on reversal of share acquisition rights	1,302	350
Total extraordinary income	1,302	350
Loss before income taxes	(562,043)	(538,670)
Income taxes-current	1,915	1,620
Total income taxes	1,915	1,620
Net loss	(563,958)	(540,290)

(3) Interim Statements of Cash Flows

Thousand yen

	Six Months Ended Jun. 30, 2024 (Jan. 1, 2024 to Jun. 30, 2024)	Six Months Ended Jun. 30, 2025 (Jan. 1, 2025 to Jun. 30, 2025)
Cash flows from operating activities		
Loss before income taxes	(562,043)	(538,670)
Depreciation and amortization	586	—
Subsidy income	(19,738)	—
Decrease (increase) in notes and accounts receivable-trade	32,500	11,689
Decrease (increase) in inventories	11,664	(495)
Decrease (increase) in prepaid expenses	(40,692)	(30,787)
Decrease (increase) in advance payments	(20,111)	(2,249)
Decrease (increase) in consumption taxes refund receivable	7,749	8,335
Increase (decrease) in notes and accounts payable-trade	(14,720)	9,632
Increase (decrease) in accounts payable-other	(53,467)	(75,231)
Increase (decrease) in accrued expenses	(1,218)	(18,124)
Other, net	(11,621)	(33,403)
Subtotal	(671,113)	(669,305)
Interest income received	17	771
Interest paid	(1,282)	(1,940)
Income taxes paid	(5,010)	(3,240)
Income taxes refund	—	708
Net cash used in operating activities	(677,388)	(673,006)
Cash flows from investing activities		
Net cash provided by investing activities	—	—
Cash flows from financing activities		
Increase in short term loans payable	22,600	—
Decrease in short term loans payable	(21,500)	(21,000)
Proceeds from issuance of common shares	454,390	105,678
Net cash provided by (used in) financing activities	455,490	84,678
Net increase (decrease) in cash and cash equivalents	(221,898)	(588,328)
Cash and cash equivalents as of the beginning of the year	1,325,554	2,063,280
Cash and cash equivalents as of the end of the period	1,103,656	1,474,952

(4) Notes to Interim Financial Statements

(Notes to Going Concern Assumptions)

Not applicable.

(Notes on Substantial Changes in Shareholders' Equity)

During the second cumulative period, the balance of capital stock and capital reserve increased separately by ¥70,033 thousand mainly due to exercise of the Subscription Rights to Shares. As a res ult, as of June 30, 2025, the balance of capital stock and capital reserve came to ¥1,065,558 thousand and ¥2,005,832 thousand, respectively.

(Important Subsequent Events)

Not applicable.